preclinical models

Related by string. Preclinical Models * Preclinical : preclinical compounds . preclinical toxicology . preclinical studies . preclinical efficacy . vivo preclinical . preclinical pharmacology . Preclinical studies suggest / modeled . Models . modeling . Modeling . Modeled . Model : Super Late Model . Super Late Models . Next Inning model . Late Model Series . Limited Late Model . 3D modeling * *

Related by context. All words. (Click for frequent words.) 73 preclinical studies 70 Preclinical studies 66 xenograft models 66 vitro studies 66 preclinical 65 anti angiogenic 65 vivo 64 preclinical efficacy 64 antitumor activity 64 neuroprotective properties 64 vivo efficacy 64 selective inhibition 64 vidofludimus 63 mGluR2 NAM 63 OXi# 63 potent antitumor activity 63 anti proliferative 63 PXD# 63 pharmacological chaperone 63 potent inhibitor 62 ENMD # 62 INGN 62 mouse xenograft models 62 Hsp# inhibitors 62 Symadex 62 CGEN # 62 anti fibrotic 62 HDAC inhibitor 62 oral prodrug 61 small molecule inhibitors 61 anti amnesic 61 preclinically 61 induces apoptosis 61 PSN# [002] 61 antitumor effects 61 CYT# potent vascular disrupting 61 novel VDA molecule 61 orally administered inhibitor 61 CTGF 61 antitumor 61 tolerability profile 60 neurotrophic 60 IAP inhibitor 60 APOPTONE 60 anti leukemic 60 antitumor efficacy 60 induce apoptosis 60 novel peptide 60 HDAC inhibitors 60 AQ4N 60 CCR2 60 Azedra 60 targeting CD# 60 S1P 60 anticancer activity 60 JAK inhibitor 60 JAK1 60 TLR8 60 potently inhibited 60 cytoprotective 60 oral bioavailability 60 investigational humanized monoclonal antibody 60 receptor agonist 60 antiangiogenic activity 60 CA4P 60 OMP #M# 59 vascular disrupting agents 59 Hsp# inhibition 59 GRN#L 59 INCB# [001] 59 ANG# 59 varespladib 59 alagebrium 59 selective modulator 59 milatuzumab 59 vascular disrupting agent 59 Seliciclib 59 pan HDAC inhibitor 59 hematological cancers 59 cannabinor 59 Enzastaurin 59 AT1R 59 CYT# 59 orally bioavailable 59 Factor VIIa 59 small molecule 59 fibrotic disease 59 immunomodulatory 59 HDAC inhibition 59 Archexin 59 TRIOLEX 59 Homspera 59 demonstrated antitumor activity 59 Tarvacin TM 59 pharmacodynamic PD 59 ganetespib 59 PTP 1B 59 MEK inhibitors 59 BiTE antibodies 59 JAK2 inhibitors 59 nonclinical studies 59 Xanafide 59 protein kinase inhibitor 59 PEG SN# 59 histone deacetylase inhibitor 59 neuroprotective 59 immune modulation 59 PRT# 58 FGFR 58 tumor vasculature 58 multi kinase inhibitor 58 JAK inhibitors 58 enzastaurin 58 selectively inhibits 58 PEG Interferon lambda 58 immunomodulatory effects 58 Virulizin ® 58 vaccine GRNVAC1 58 Sphingomab 58 small molecule tyrosine 58 Triolex 58 pro apoptotic 58 CTAP# Capsules 58 mTOR inhibitors 58 Nanobodies 58 trodusquemine 58 radiation sensitizer 58 Exherin TM 58 BRAF inhibitor 58 IGF 1R 58 CCR9 58 hypoxia activated prodrug 58 fosbretabulin 58 IL 1β 58 p# inhibitor 58 TLR9 58 depsipeptide 58 VEGF receptor 58 MGd 58 CORT # 58 Carfilzomib 58 Preclinical studies suggest 58 HGS ETR2 58 imatinib Gleevec ® 58 EpCAM 58 HIF PH inhibitors 58 liposomal formulation 58 BNC# 58 small molecule defensin 58 murine model 58 preclinical xenograft models 58 cMET 58 KSP inhibitors 58 hematologic malignancies 58 phase IIa clinical 58 Hedgehog pathway 58 TLR7 58 JAK2 inhibitor 58 p# inhibitors 58 inhibit tumor 58 effector function 58 humanized monoclonal antibodies 58 mitogen activated ERK kinase 58 AEG# 58 neuroprotection 58 Panzem R 58 #ME# 58 AKT inhibitor 58 RGB # 58 systemically administered 58 potent inhibition 58 alvespimycin 58 humanized monoclonal antibody 58 glucagon receptor 58 antibody MT# 57 inhibitory effects 57 CD# CEA 57 Preclinical 57 vitro experiments 57 BAL# [001] 57 potent antiproliferative 57 5 HT6 receptor 57 highly selective inhibitor 57 GAP #B# 57 MGCD# [001] 57 HQK 57 PGE2 57 vitro cytotoxicity 57 obatoclax 57 Azixa 57 effector functions 57 indibulin 57 Tyrima 57 antitumour activity 57 Bendavia 57 potently inhibit 57 Vidofludimus 57 GRNCM1 57 orthotopic model 57 small molecule inhibitor 57 Apoptone 57 XmAb# 57 ALN TTR# 57 BiTE antibody 57 antisense inhibition 57 molecular biomarkers 57 cyclin dependent kinases CDKs 57 partial agonist 57 MCSP respectively 57 immunotherapeutic 57 favorable pharmacokinetic profile 57 elacytarabine 57 Aplidin 57 #D#C# 57 CB2 selective receptor agonist 57 GM CSF 57 alpha7 57 adenoviral 57 HGS ETR1 57 XL# inhibits 57 CCR9 antagonist 57 pro angiogenic 57 CD# expressing 57 chemotherapeutics 57 mdx mouse 57 RNA antagonist 57 pharmacodynamic profile 57 huC# DM4 57 small molecule agonists 57 receptor antagonists 57 PI3K/mTOR 57 ALN TTR 57 SERMs 57 siRNA mediated 57 entinostat 57 delta isoform 57 AAG geldanamycin analog 57 tumorigenicity 57 mTOR inhibition 57 tumor xenograft models 57 Onconase 57 erythropoietic 57 Squalamine 57 PS# [001] 57 pharmacologic 57 AMPK activators 57 ARIKACE ™ 57 Gleevec resistant 57 pancreatic colon 57 anti CD3 57 rBChE 57 selective inhibitors 57 PKC# 57 potent anticancer 57 CD# antibody [001] 57 Hsp# inhibitor 56 epothilones 56 Ocrelizumab 56 TNFalpha 56 resolvin 56 HCV protease 56 Exelixis compounds 56 PD LID 56 oncology indications 56 angiogenesis inhibitor 56 novel topoisomerase 56 Abeta# 56 TRO# 56 RNAi therapeutic 56 PI3K Akt 56 pharmacodynamic 56 ESBA# 56 c MYC 56 Nanobody ® 56 IL 1ß 56 pharmacodynamic profiles 56 Ganetespib 56 IMC A# 56 reversible inhibitor 56 BZL# 56 Phase Ib clinical 56 Synavive 56 small molecule activator 56 immune stimulatory 56 JAK#/JAK# 56 vitro 56 cyclophilin inhibitors 56 CDK inhibitor 56 kinase inhibitor 56 CCX# 56 angiogenesis inhibition 56 myeloproliferative disorders 56 JAK3 56 receptor subtypes 56 XL# [003] 56 hedgehog pathway 56 MEK inhibitor 56 multitargeted 56 OncoVex 56 Zybrestat 56 TKM ApoB 56 HGS# 56 transgenic mouse model 56 LPS induced 56 potent antiviral 56 IMC #B 56 psoriasis rheumatoid arthritis 56 proteasome inhibitor 56 hypoxia inducible factor 56 kinase inhibition 56 elesclomol 56 small molecule activators 56 novel anticancer 56 receptor inhibitor 56 Amplimexon 56 mGluR5 NAM 56 telomerase therapeutic 56 EZN 56 inducible nitric oxide synthase 56 pertuzumab 56 transgenic mouse models 56 receptor tyrosine kinase inhibitor 56 renal fibrosis 56 solid tumors 56 solithromycin 56 GSK3B 56 Pharmacokinetic studies 56 antisense inhibitors 56 isoform selective 56 S/GSK# 56 Tarvacin 56 GLYX 56 telomerase inhibitor 56 humanized anti 56 pharmacokinetic properties 56 immunostimulatory 56 class mGluR5 inhibitor 56 sunitinib Sutent ® 56 disease modifying 56 PI3K delta 56 EGFR HER2 56 ISIS # 56 neurotrophic factors 56 antiangiogenic 56 RNAi therapeutic targeting 56 neuronal dysfunction 56 Sym# 56 peptide antigens 56 cilengitide 56 RDEA# 56 experimental autoimmune encephalomyelitis 56 selective agonist 56 #HT#A 56 humanized antibody 56 antiviral activity 56 PSMA ADC 56 PI3K 56 HCD# [002] 56 tanespimycin 56 HGS ETR1 mapatumumab 56 iroxanadine 56 MAb 56 HIF 1alpha 56 Imprime PGG 56 p# activation 56 TNFa 56 kinase inhibitors 56 cytotoxicity 56 LPA1 receptor 56 RLY# 56 huN# DM1 56 Wnt signaling pathway 56 TG# [003] 56 Posiphen 55 proteasome inhibitors 55 DXL# 55 TRV# [001] 55 neuroregenerative 55 HuLuc# 55 imetelstat 55 Janus kinase 55 upregulation 55 VEGF receptors 55 tolerability 55 eNOS 55 muscarinic 55 HSP# inhibitor 55 tkRNAi technology 55 NOD mice 55 tolerability profiles 55 chemopreventive agent 55 NF kB pathway 55 pharmacodynamic properties 55 CBLC# 55 MAPK pathway 55 diabetic neuropathic pain 55 telomerase inhibitor drug 55 potent anti angiogenic 55 sd rxRNA compounds 55 XL# anticancer compounds 55 otelixizumab 55 monoclonal antibody 55 DOS# 55 GRN# 55 synthetic retinoid 55 triggers apoptosis programmed 55 leukemic stem cells 55 ON #.Na 55 LSI #P 55 ASONEP 55 Serdaxin 55 leukocyte adhesion 55 geldanamycin 55 aurora kinase 55 AMPAKINE 55 NEUGENE 55 Bezielle 55 GMX# 55 vorinostat 55 PolyMedix defensin 55 anticancer agent 55 epithelial cancers 55 rNAPc2 55 ansamycin 55 PPARγ 55 Omacetaxine 55 HuMax EGFr 55 ERK1 2 55 lysosomal 55 siRNA therapeutic 55 mertansine 55 flavopiridol 55 PCK# 55 Fc fusion protein 55 FAAH 55 inhibitor RG# 55 polymerase inhibitor 55 Traficet EN 55 velafermin 55 combinability 55 riociguat 55 immunological responses 55 phosphate S1P 55 estrogen receptor beta 55 KRN# 55 TLR8 agonist 55 trastuzumab Herceptin R 55 potent inhibitors 55 Microplasmin 55 taxane resistant 55 cytotoxic 55 UsiRNAs 55 Hsp# Inhibitor 55 Oral NKTR 55 selective inhibitor 55 Galectin 55 TPI ASM8 55 Fleximer 55 VDAs 55 erlotinib Tarceva ® 55 sodium glucose cotransporter 55 Thiovir 55 factor TNF 55 panobinostat 55 pharmacokinetic profile 55 HIF 1α 55 PI3K inhibitor 55 oral JAK1 55 iNOS 55 biodistribution 55 immune modulating 55 TLR9 agonists 55 MultiStem 55 anticancer therapeutics 55 MET amplification 55 ERK pathway 55 anticancer agents 55 pathophysiological effects 55 p# mitogen activated 55 miR #a [001] 55 antiviral potency 55 NP2 Enkephalin 55 Golimumab 55 neratinib 55 Nanobody 55 peripherally acting 55 tolerogenic 55 MORAb 55 neurogenic 55 OvaRex R 55 lung fibrosis 55 LT NS# 55 prolyl hydroxylase inhibitors 55 mTOR mammalian target 55 immunomodulation 55 NTx TM -# 55 Ceflatonin 55 HIF PHI 55 BiTE 55 immune mediated 55 oxidative stress inducer 55 MTP inhibitor 55 romidepsin 55 FK# 55 sigma receptors 55 polycythemia vera PV 55 Phase IIb trials 55 investigational monoclonal antibody 55 proliferative diseases 55 Fibroblast Growth Factor Receptor 55 P#X# 55 seliciclib CYC# 55 PC# cells 55 MDV# 55 interleukin IL -# 55 CR# vcMMAE 55 siRNA therapeutics 55 ANAVEX #-# [003] 55 heavily pretreated 55 anti EGFR antibody 55 mu opioid receptor antagonist 55 selectively inhibited 55 Aurora kinase 55 ZFP Therapeutic 55 NS#/#A protease 55 histone deacetylase HDAC inhibitor 55 mapatumumab 55 ocular formulation 55 tafamidis 55 davunetide intranasal AL 55 ANAVEX #-# [001] 55 PLK1 55 selective kinase inhibitor 55 TTR gene 55 antitumoral 55 MEK inhibitor RDEA# 55 VEGF inhibitors 55 antiapoptotic 55 receptor antagonist 55 squalamine 55 ACZ# 55 LHRH antagonists 55 Multimeric 55 Curaxin CBLC# 55 TNFα 55 CG# [003] 55 HE# [002] 55 AAV2 55 mda 7 55 inhibition 55 vivo validation 55 prognostic markers 55 selectively inhibit 55 isotypes 55 prodrugs 55 personalized immunotherapy 55 IAP inhibitors 55 ARRY 55 Voreloxin 55 JAK2 55 Nanobodies ® 55 metaglidasen 55 AVN# [001] 55 anti atherogenic 55 YONDELIS 55 Darinaparsin 54 biased ligand 54 IMGN# 54 Raf MEK ERK 54 PI3K/Akt pathway inhibitor 54 Eg5 54 XL# XL# 54 Epratuzumab 54 agonist 54 Lisofylline 54 IGF IR 54 inhibit metastasis 54 neuro protective 54 PRTX 54 intratumoral injection 54 MMP2 54 MEK ERK 54 IgG1 antibody 54 resolvins 54 nicotinic 54 Vitaxin 54 EndoTAG TM -1 54 monoclonal antibody MAb 54 TGR5 54 cardiac toxicity 54 EGF receptor 54 MAGE A3 ASCI 54 2 inhibitor CYT# 54 somatostatin 54 neuroprotective effects 54 SARMs 54 OncoVEX GM CSF 54 mecamylamine 54 Factor VEGF 54 JVRS 54 DFMO 54 humanized monoclonal 54 monoclonal antibodies 54 V#F mutation 54 immunomodulator 54 anticancer therapies 54 ErbB3 HER3 54 CD# [002] 54 HspE7 54 veltuzumab 54 gastrin 54 OX1 54 antagomirs 54 myeloproliferative diseases 54 siRNA 54 TRX# 54 pharmacokinetic 54 immune modulators 54 relapsed refractory 54 Safinamide 54 EGFR signaling 54 xenografts 54 bafetinib 54 HDAC Inhibitor 54 PNP inhibitor 54 NeuroVax TM 54 selective adenosine 54 cytokines IL 54 leukemia AML 54 protein tyrosine phosphatase 1B 54 LEX System 54 investigational compound 54 ImmunoVEX HSV2 54 apremilast 54 Epothilones 54 cyclophilin inhibitor 54 Hedgehog signaling 54 liposomal 54 pharmacokinetic profiles 54 ALN VSP 54 investigational compounds 54 remyelination 54 human monoclonal antibody 54 miR #a [002] 54 Phase IIa 54 antisense drugs 54 neutralizing antibody 54 therapeutic antibodies 54 5 HT4 receptor 54 TRAIL induced apoptosis 54 activin 54 antiproliferative activity 54 MAP# 54 cardioprotective effects 54 leukocyte recruitment 54 investigational hepatitis C 54 rxRNA 54 Atiprimod 54 omega interferon 54 R#/MEM # 54 inhibitory receptor 54 Anticalin ® 54 ERK signaling 54 receptor agonists 54 uricase 54 MyVax R 54 PSN# [001] 54 TNF α 54 targeted radiotherapeutic 54 syngeneic 54 multiple myeloma MM 54 plasma kallikrein inhibitor 54 Smac mimetics 54 acadesine 54 multikinase inhibitor 54 Phase 1b clinical trials 54 EGFr 54 chemopreventive 54 NGX# 54 GW# [003] 54 Akt inhibitor 54 mimetics 54 LEP ETU 54 Angiolix 54 chemoresistance 54 volociximab 54 Alpharadin 54 immunoregulatory 54 synthetic peptide 54 therapeutically relevant 54 Debio 54 talactoferrin 54 matrix metalloproteinases 54 humanized antibodies 54 #beta HSD1 54 Vandetanib 54 inhibits tumor 54 targeting PCSK9 54 kidney urologic 54 RANKL 54 pharmacodynamic effects 54 axitinib 54 lumiliximab 54 INCB# [002] 54 immune modulatory 54 neurotoxicity 54 peptibody 54 ErbB3 54 atacicept 54 oral FTY# 54 lintuzumab SGN 54 ELACYT 54 TLR antagonists 54 Lisofylline LSF 54 PEGylated interferon beta 1a 54 chemokine receptor 54 Phase #b/#a clinical 54 alkylating agent 54 eculizumab 54 ALK inhibitor 54 AP# [003] 54 immune modulator 54 selective antagonist 54 HDAC 54 5 HT2A receptor 54 tesetaxel 54 CEQ# 54 potent cytotoxic 54 splice variants 54 ENaC 54 prognostic indicator 54 HuMax CD# 54 JAK2 enzyme 54 p# MAPK 54 androgen receptor AR 54 vaso occlusive crisis 54 THR beta agonist 54 bortezomib 54 Perifosine 54 HCV protease inhibitors 54 SRT# [003] 54 CRLX# 54 OncoVEX 54 induced tumor regression 54 neovascular diseases 54 chemo resistant 54 microglial activation 54 adult mesenchymal stem 54 antibody mediated 54 pro inflammatory cytokines 54 Tβ4 54 plasma kallikrein 54 mGluR5 negative 54 polymerase inhibitors 54 vivo preclinical studies 54 FasL 54 alpha folate receptor 54 CYC# 54 c MET 54 Blinatumomab 54 KL4 surfactant 54 SGLT2 54 mitotic kinesins 54 phase IIb trial 54 NTDDS 54 clusterin 54 INCB# [003] 54 DGAT1 inhibitors 54 CD# monoclonal antibody 54 transthyretin TTR mediated amyloidosis 54 sunitinib malate 54 PLX cells 54 PTHrP 54 CXCR7 54 cleavable linker 54 SGLT inhibitors 54 VEGF induced 54 bone metastasis 53 OHR/AVR# 53 Inhibition 53 Azedra TM 53 XL# XL# XL# 53 HDACi 53 CD8 responses 53 vivo potency 53 induced apoptosis 53 forodesine 53 E#F# 53 IRX 2 53 antiproliferative effects 53 Interferon alpha 53 Tamibarotene 53 dyskinesia PD LID 53 PARP inhibitors 53 Entereg R 53 MET VEGFR2 53 signaling pathways 53 Zalypsis 53 phase 2a 53 parathyroid hormone PTH 53 interferon IFN 53 pharmacodynamic biomarkers 53 PKCi 53 A3 adenosine receptor 53 superficial bladder cancer 53 thioredoxin 53 neurodegenerative diseases 53 ALB # 53 hematological malignancies 53 R roscovitine 53 HCV replication 53 serotonin receptor 53 signaling cascades 53 anti angiogenic agent 53 peroxisome proliferator activated 53 pathological hallmarks 53 p# alpha [001] 53 lenalidomide Revlimid R 53 immunotoxin 53 receptor partial agonist 53 cardioprotection 53 Inosine 53 TLR antagonist 53 RH1 53 tezampanel 53 ProSavin 53 PI3K pathway 53 Smad3 53 Beta catenin pathway 53 imexon 53 Anticalin R 53 PDE4 inhibitor 53 CD#L 53 insulin sensitizing 53 pleiotropic 53 PI3K inhibitors 53 NFkB 53 CB2 receptor 53 VEGFR2 53 proto oncogene 53 beta amyloid peptide 53 apoptotic pathway 53 ischemic diseases 53 trastuzumab Herceptin ® 53 M2 subunit 53 GGF2 53 bexarotene 53 tyrosine kinase inhibitor 53 neuroprotectant 53 therapeutic modality 53 MetAP2 53 rindopepimut 53 Panzem 53 decitabine 53 Tß4 53 Trofex 53 M1 muscarinic 53 Solazed TM 53 Cannabinor 53 partial agonists 53 Hedgehog signaling pathway 53 docetaxel Taxotere ® 53 IMA# 53 molecularly targeted 53 antimitotic 53 GDIR 53 peripheral blood mononuclear 53 tissue fibrosis 53 SYN# 53 LNP formulations 53 anticancer therapy 53 teduglutide 53 Lixivaptan 53 BN# [002] 53 Curaxin 53 antifibrotic 53 Prodarsan ® 53 chemokine receptors 53 Personalized Immunotherapy 53 CaPre TM 53 thalidomide Thalomid 53 AKT1 53 familial amyloidotic polyneuropathy FAP 53 nicotinic alpha 7 53 STAT3 signaling 53 inflammatory cytokines 53 TÎ ² 4 53 anti angiogenic agents 53 PTP1B 53 essential thrombocythemia ET 53 sodium thiosulfate STS 53 PEGylated interferon 53 Daclizumab 53 vivo preclinical 53 pharmacologic intervention 53 Parkinson disease levodopa induced 53 iSONEP 53 fibrotic diseases 53 biologic pathways 53 sd rxRNA 53 potency selectivity 53 gamma secretase inhibitor 53 Kahalalide F 53 Lorianne Masuoka MD 53 NEUGENE antisense 53 NADPH oxidase 53 CDK inhibitors 53 kallikrein 53 Phase IIb clinical trials 53 sphingosine 1 53 thetreatment 53 nucleotide analogs 53 immunological diseases 53 PDE# inhibitors 53 HER3 53 Cyclin E 53 Bavituximab 53 PDE#A 53 extracellular signal 53 immune responses 53 hyperphosphorylation 53 LY# [003] 53 Presents Preclinical Data 53 safety tolerability pharmacokinetic 53 upregulated 53 fatty acid oxidation 53 ISTODAX 53 IL #p# 53 microtubule targeting 53 PI3 kinase 53 PROCHYMAL 53 pomalidomide 53 autoimmune diseases 53 Hsp# [002] 53 overactivation 53 Telintra 53 encapsulates siRNAs 53 preclinical compounds 53 Phase IIa clinical trials 53 neuroendocrine cancers 53 bardoxolone methyl 53 TLR9 agonist 53 myelofibrosis polycythemia vera 53 IL #E 53 bioactive lipids 53 axonal regeneration 53 Valortim 53 inflammatory diseases 53 agonists 53 K ras mutations 53 myeloproliferative 53 androgen independent 53 Phase 1b trial 53 orally dosed 53 anti CTLA 53 antithrombotic 53 ADP receptor antagonist 53 pediatric malignancies 53 MLN# 53 Romidepsin 53 IFN γ 53 inhibiting tumor 53 diabetic nephropathy 53 NEUVENGE 53 LBH# 53 DiLA2 liposomes 53 Phase 2a clinical 53 antiangiogenic therapy 53 VAPRISOL 53 ProLindac 53 targeted antifolate 53 cytokine 53 Aurora Kinase 53 PEP# [003] 53 Proxinium TM 53 oral dosing 53 delipidation 53 cobiprostone 53 M2PK 53 XmAb ™ 53 Nicole Onetto MD 53 Histone deacetylase 53 antisense inhibitor 53 NOD SCID mice 53 epithelial tumors 53 Phase Ib clinical trials 53 viral kinetics 53 highly immunogenic 53 Aplidin R 53 MT#/MEDI-# 53 fusion protein 53 poly ADP ribose polymerase 53 inflammatory mediators 53 pharmacodynamic markers 53 RoACTEMRA 53 immuno modulatory 53 hematologic cancers 53 virus HCV protease inhibitor 53 FGFR2

Back to home page